PMID- 38264644
OWN - NLM
STAT- MEDLINE
DCOM- 20240125
LR  - 20240402
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Defining genetic diversity of rhesus macaque Fcgamma receptors with long-read RNA 
      sequencing.
PG  - 1306292
LID - 10.3389/fimmu.2023.1306292 [doi]
LID - 1306292
AB  - Fcgamma receptors (FcgammaRs) are membrane-bound glycoproteins that bind to the fragment 
      crystallizable (Fc) constant regions of IgG antibodies. Interactions between IgG 
      immune complexes and FcgammaRs can initiate signal transduction that mediates 
      important components of the immune response including activation of immune cells 
      for clearance of opsonized pathogens or infected host cells. In humans, many 
      studies have identified associations between FcgammaR gene polymorphisms and risk of 
      infection, or progression of disease, suggesting a gene-level impact on 
      FcgammaR-dependent immune responses. Rhesus macaques are an important translational 
      model for most human health interventions, yet little is known about the breadth 
      of rhesus macaque FcgammaR genetic diversity. This lack of knowledge prevents 
      evaluation of the impact of FcgammaR polymorphisms on outcomes of preclinical studies 
      performed in rhesus macaques. In this study we used long-read RNA sequencing to 
      define the genetic diversity of FcgammaRs in 206 Indian-origin Rhesus macaques, 
      Macaca mulatta. We describe the frequency of single nucleotide polymorphisms, 
      insertions, deletions, frame-shift mutations, and isoforms. We also index the 
      identified diversity using predicted and known rhesus macaque FcgammaR and Fc-FcgammaR 
      structures. Future studies that define the functional significance of this 
      genetic diversity will facilitate a better understanding of the correlation 
      between human and macaque FcgammaR biology that is needed for effective translation 
      of studies with antibody-mediated outcomes performed in rhesus macaques.
CI  - Copyright (c) 2024 Conley, He, Easterhoff, Kirshner, Cocklin, Meyer, Hoxie, Berry, 
      Bradley, Tolbert, Pazgier, Tomaras, Schmitz, Moody, Wiehe and Pollara.
FAU - Conley, Haleigh E
AU  - Conley HE
AD  - Department of Surgery, Duke University School of Medicine, Duke University, 
      Durham, NC, United States.
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - He, Max M
AU  - He MM
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Easterhoff, David
AU  - Easterhoff D
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Kirshner, Helene Fradin
AU  - Kirshner HF
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Cocklin, Sarah L
AU  - Cocklin SL
AD  - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, 
      Harvard Medical School, Boston, MA, United States.
FAU - Meyer, Jacob
AU  - Meyer J
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Hoxie, Taylor
AU  - Hoxie T
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Berry, Madison
AU  - Berry M
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Bradley, Todd
AU  - Bradley T
AD  - Genomic Medicine Center, Children's Mercy Kansas City, Kansas City, MO, United 
      States.
FAU - Tolbert, William D
AU  - Tolbert WD
AD  - Infectious Disease Division, Department of Medicine, Uniformed Services 
      University of the Health Sciences, Bethesda, MD, United States.
FAU - Pazgier, Marzena
AU  - Pazgier M
AD  - Infectious Disease Division, Department of Medicine, Uniformed Services 
      University of the Health Sciences, Bethesda, MD, United States.
FAU - Tomaras, Georgia D
AU  - Tomaras GD
AD  - Department of Surgery, Duke University School of Medicine, Duke University, 
      Durham, NC, United States.
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Schmitz, Joern E
AU  - Schmitz JE
AD  - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, 
      Harvard Medical School, Boston, MA, United States.
FAU - Moody, Michael Anthony
AU  - Moody MA
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Wiehe, Kevin
AU  - Wiehe K
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
FAU - Pollara, Justin
AU  - Pollara J
AD  - Department of Surgery, Duke University School of Medicine, Duke University, 
      Durham, NC, United States.
AD  - Duke Human Vaccine Institute, Duke University School of Medicine, Duke 
      University, Durham, NC, United States.
LA  - eng
GR  - P01 AI120756/AI/NIAID NIH HHS/United States
GR  - P01 AI131251/AI/NIAID NIH HHS/United States
GR  - P01 AI162242/AI/NIAID NIH HHS/United States
GR  - T32 AI007392/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20240109
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Receptors, IgG)
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Humans
MH  - Animals
MH  - Macaca mulatta
MH  - *Receptors, IgG
MH  - Sequence Analysis, RNA
MH  - *Antigen-Antibody Complex
MH  - Frameshift Mutation
MH  - Immunoglobulin G
MH  - Membrane Glycoproteins
PMC - PMC10803544
OTO - NOTNLM
OT  - Fc receptor
OT  - FcgammaR SNPs
OT  - FcgammaR structures
OT  - Long-read RNA sequencing
OT  - genetic diversity
OT  - rhesus macaques
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The author(s) declared that they were an editorial board 
      member of Frontiers, at the time of submission. This had no impact on the peer 
      review process and the final decision.
EDAT- 2024/01/24 06:43
MHDA- 2024/01/25 06:43
PMCR- 2023/01/01
CRDT- 2024/01/24 03:56
PHST- 2023/10/03 00:00 [received]
PHST- 2023/12/20 00:00 [accepted]
PHST- 2024/01/25 06:43 [medline]
PHST- 2024/01/24 06:43 [pubmed]
PHST- 2024/01/24 03:56 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1306292 [doi]
PST - epublish
SO  - Front Immunol. 2024 Jan 9;14:1306292. doi: 10.3389/fimmu.2023.1306292. 
      eCollection 2023.